Brief: Biocartis And Ophiomics To Collaborate On Liver Cancer Test

Biocartis NV

08/02/2022 06:19

Feb 8 (Reuters) - BIOCARTIS GROUP NV  BCART.BR :
    * BIOCARTIS AND OPHIOMICS TO COLLABORATE ON  LIVER CANCER
TEST
    * COLLABORATION TO FOCUS ON COMMERCIALIZATION OF
HEPATOPREDICT™, A
PROGNOSTIC GENE EXPRESSION SIGNATURE TEST TO IDENTIFY WHICH
PATIENTS WILL BENEFIT FROM LIVER TRANSPLANTATION
    * HEPATOPREDICT™ WILL BE LAUNCHED AS A CE-MARKED IVD MANUAL
KIT IN
Q1 2022
    * PARTNERSHIP WILL INITIALLY FOCUS ON BIOCARTIS'
COMMERCIALIZATION
OF MANUAL KIT IN EUROPE
    * OPHIOMICS AND BIOCARTIS AIM TO INITIATE DEVELOPMENT OF
FULLY
AUTOMATED VERSION OF TEST ON BIOCARTIS' DECENTRALIZED IDYLLA™
PLATFORM

Source text for Eikon:  ID:nGNE41dYDh 
Further company coverage:  BCART.BR 

 (Gdansk Newsroom)
 ((charlotte.lavin@thomsonreuters.com; +48451017675;))